WUXI BIO: POSITIVE PROFIT ALERT

Wuxi Bio has released its preliminary financial results for the 2025 fiscal year, projecting a 16.7% increase in annual revenue to RMB 21.8 billion, with gross margin improving by 5 percentage points to 46.0%. The company anticipates a 45.3% growth in net profit to RMB 5.733 billion, and a 46.3% rise in net profit attributable to shareholders to RMB 4.908 billion. Adjusted non-IFRS net profit is expected to grow by 22.0% to RMB 6.586 billion.The growth in performance is primarily attributed to the successful execution of the company's 'Follow and Win Molecules' strategy, along with rapid advancements in technology platforms such as bispecific antibodies and ADCs. The company has expanded its comprehensive biopharmaceutical R&D service offerings, including research and discovery services, pre-IND development services, and clinical...Show More

Wuxi Bio has released its preliminary financial results for the 2025 fiscal year, projecting a 16.7% increase in annual revenue to RMB 21.8 billion, with gross margin improving by 5 percentage points to 46.0%. The company anticipates a 45.3% growth in net profit to RMB 5.733 billion, and a 46.3% rise in net profit attributable to shareholders to RMB 4.908 billion. Adjusted non-IFRS net profit is expected to grow by 22.0% to RMB 6.586 billion.The growth in performance is primarily attributed to the successful execution of the company's 'Follow and Win Molecules' strategy, along with rapid advancements in technology platforms such as bispecific antibodies and ADCs. The company has expanded its comprehensive biopharmaceutical R&D service offerings, including research and discovery services, pre-IND development services, and clinical and commercial production services. Additionally, cost savings and efficiency improvements have been achieved through the Wuxi Bio Lean Operations Management System (WBS) and digital solutions.The production capacity at the company’s European manufacturing base continues to increase, with both existing and new capacity utilization rates continuously optimized. Furthermore, the company has generated investment income from its portfolio, further driving earnings growth. The company is expected to release its audited full-year 2025 financial results report on March 24, 2026.